The healthcare and life sciences companies that Syncona invests in should be hot tickets. These sectors are abuzz with ideas, while demand from both the public and the medical world is stronger than ever.
Syncona, an investment trust, has a declared purpose “to extend and enhance human life ... by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.”
Chris Hollowood, chief executive, said yesterday: “Earlier this financial year, we set out an ambitious plan to organically scale the business to £5 billion of net assets within ten years. At the heart of this is improving shareholder returns. Growing the asset base will allow us to operate our model at scale, driving balance sheet efficiency and enabling enhanced
